FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* FORMELA JEAN FRANCOIS					2. Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [ NTLA ]						(Ch	elationship deck all applic	able) r	p Perso	10% Ow	ner
					3. Date of Earliest Transaction (Month/Day/Year) 06/18/2020							Officer below)	(give title		Other (s <sub>i</sub> below)	pecify
40 ERIE STREET; SUITE 130				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable					
(Street)	IDGE M	A	02139								Line	X Form fi	led by One led by More	•	Ü	
(City)	(S	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Transactior te onth/Day/Yo	Execution Date,		3. Transactio Code (Inst	ansaction Disposed Of (D) (Instr. 3, ode (Instr. 5)			5. Amour Securitie Beneficia Owned F Reported	es Forn ally (D) of following (I) (Ir		Direct C ndirect E r. 4)	7. Nature of Indirect Beneficial Ownership	
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code (				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly C	Donership Form: Direct (D) Or Indirect I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$20.72	06/18/2020		A		19,000		(1)	06/17/2030	Common Stock	19,000	\$0.00	19,000		D	

## **Explanation of Responses:**

1. This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

## Remarks:

/s/ Jose Rivera, Attorney-in-

**Fact** 

06/19/2020

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.